ROS1-rearranged non-small cell lung carcinoma

From Libre Pathology

Revision as of 02:51, 31 December 2019 by Michael (talk | contribs) (→‎Molecular)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

Micrograph showing a ROS1-positive adenocarcinoma of the lung. ROS1 immunostain.

ROS1-rearranged non-small cell lung carcinoma is a subtype of non-small cell lung carcinoma that can be treated with ALK inhibitors.^[1]

General

ROS1-rearrangements are seen in approximately 1-2% of non-small cell carcinoma.^[2]
Respond to target therapy, e.g. crizotinib.^[3]

Microscopic

Features:

Histology not definitive; however, predictive features are:^[4]
- Cribriform structure.
- Psammoma bodies

Note:

Most common pattern varies by specimen type:^[4]
- Biopsy specimens: solid pattern most common.
- Resection specimens: acinar pattern most common.

Images

NSmCC - low mag.
NSmCC - intermed. mag.
NSmCC - high mag.
NSmCC - very high mag.
NSmCC - TTF-1 - high mag.
NSmCC - napsin A - high mag.

IHC

ROS1 +ve.

Images

NSmCC - ROS1 - low mag.
NSmCC - ROS1 - intermed. mag.
NSmCC - ROS1 -high mag.

Molecular

ROS1 rearrangements can be demonstrated dual-colour break apart FISH probes.^[5]

See also

References

↑ Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
↑ "Targeted therapies for ROS1-rearranged non-small cell lung cancer". Drugs Today 55 (10): 641–652. October 2019. doi:10.1358/dot.2019.55.10.3030646. PMID 31720561.
↑ "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001". Ann. Oncol. 30 (7): 1121–1126. July 2019. doi:10.1093/annonc/mdz131. PMC 6637370. PMID 30980071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637370/.
↑ ^4.0 ^4.1 "A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features". PLoS ONE 11 (9): e0161861. 2016. doi:10.1371/journal.pone.0161861. PMC 5029801. PMID 27648828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029801/.
↑ "Testing for ROS1 in non-small cell lung cancer: a review with recommendations". Virchows Arch. 469 (5): 489–503. November 2016. doi:10.1007/s00428-016-2000-3. PMC 5082594. PMID 27535289. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082594/.

Retrieved from "https://librepathology.org/w/index.php?title=ROS1-rearranged_non-small_cell_lung_carcinoma&oldid=50607"